AB Science (ABS.PA) delays AML and ALS trial restarts after “for cause” GCP inspection
AB Science revised its development plan after a “for cause” sponsor Good Clinical Practice inspection by French, Danish and Greek authorities. The Phase 1 AB8939 AML trial is targeted to resume in Q1 2027, and the masitinib Phase 3 ALS trial was pushed to Q4 2027, subject to health-authority benefit-risk assessments an